Targeted development of specific biomarkers of endometrial stromal cell differentiation using bioinformatics: the IFITM1 model
When classifying cellular uterine mesenchymal neoplasms, histological distinction of endometrial stromal from smooth muscle neoplasms can be difficult. The only widely established marker of endometrial stromal differentiation, CD10, has marginal specificity. We took a bioinformatics approach to iden...
Gespeichert in:
| Veröffentlicht in: | Modern pathology 2014-04, Vol.27 (4), p.569-579 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 579 |
|---|---|
| container_issue | 4 |
| container_start_page | 569 |
| container_title | Modern pathology |
| container_volume | 27 |
| creator | Parra-Herran, Carlos E Yuan, Liping Nucci, Marisa R Quade, Bradley J |
| description | When classifying cellular uterine mesenchymal neoplasms, histological distinction of endometrial stromal from smooth muscle neoplasms can be difficult. The only widely established marker of endometrial stromal differentiation, CD10, has marginal specificity. We took a bioinformatics approach to identify more specific markers of endometrial stromal differentiation by searching the Human Protein Atlas, a public database of protein expression profiles. After screening the database using different methods, interferon-induced transmembrane protein 1 (IFITM1) was selected for further analysis. Immunohistochemistry for IFITM1 was performed using tissue sections from the selected cases of proliferative endometrium (22), secretory endometrium (6), inactive endometrium (19), adenomyosis (10), conventional leiomyoma (11), cellular leiomyoma (16), endometrial stromal nodule (2), low-grade endometrial stromal sarcoma (16), high-grade endometrial stromal sarcoma (2) and undifferentiated uterine sarcoma (2). Stained slides were scored in terms of intensity and distribution. Normal endometrial samples uniformly showed diffuse and strong IFITM1 staining. Endometrial stromal neoplasms, particularly low-grade endometrial stromal sarcoma, showed higher IFITM1 expression compared with smooth muscle neoplasms (P |
| doi_str_mv | 10.1038/modpathol.2013.123 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1512554786</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S089339522201849X</els_id><sourcerecordid>1512554786</sourcerecordid><originalsourceid>FETCH-LOGICAL-c538t-e24f28629a41aefe0ddc0a5f3767780541e183beec5cd7422c9670147defda4d3</originalsourceid><addsrcrecordid>eNp9kT9vFDEQxS0EIkfgC1AgSzQ0e_jvrQ_RRBGBk4Jojtry2eOLw6692N5INHx2vLoQIYpUlmZ-b-Z5HkKvKVlTwtX7MbnJ1Js0rBmhfE0Zf4JWVHLSEabkU7Qiass7vpXsDL0o5ZYQKqRiz9EZE6RnVLEV-r03-QgVHHZwB0OaRogVJ4_LBDb4YPEhpNHkH5DLUobo0gg1BzPgUnNrDdjCMGAXvIfcxMHUkCKeS4jHRRyiT3lsRVs-4HoDeHe123-luLmH4SV65s1Q4NX9e46-X33aX37prr993l1eXHdWclU7YMIztWFbI6gBD8Q5S4z0vN_0vSJSUKCKHwCstK4XjNntpm-_7R14Z4Tj5-jdae6U088ZStVjKItvEyHNRVNJmZSiV5uGvv0PvU1zjs3dQrU1ignVKHaibE6lZPB6yqHd6ZemRC_p6Id09JKObuk00Zv70fNhBPcg-RtHA_gJKK0Vj5D_2f3Y2I8nFbQL3oWmKjZAtOBCBlu1S-Ex-R_UiLXG</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1511838248</pqid></control><display><type>article</type><title>Targeted development of specific biomarkers of endometrial stromal cell differentiation using bioinformatics: the IFITM1 model</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>ProQuest Central UK/Ireland</source><source>Alma/SFX Local Collection</source><creator>Parra-Herran, Carlos E ; Yuan, Liping ; Nucci, Marisa R ; Quade, Bradley J</creator><creatorcontrib>Parra-Herran, Carlos E ; Yuan, Liping ; Nucci, Marisa R ; Quade, Bradley J</creatorcontrib><description>When classifying cellular uterine mesenchymal neoplasms, histological distinction of endometrial stromal from smooth muscle neoplasms can be difficult. The only widely established marker of endometrial stromal differentiation, CD10, has marginal specificity. We took a bioinformatics approach to identify more specific markers of endometrial stromal differentiation by searching the Human Protein Atlas, a public database of protein expression profiles. After screening the database using different methods, interferon-induced transmembrane protein 1 (IFITM1) was selected for further analysis. Immunohistochemistry for IFITM1 was performed using tissue sections from the selected cases of proliferative endometrium (22), secretory endometrium (6), inactive endometrium (19), adenomyosis (10), conventional leiomyoma (11), cellular leiomyoma (16), endometrial stromal nodule (2), low-grade endometrial stromal sarcoma (16), high-grade endometrial stromal sarcoma (2) and undifferentiated uterine sarcoma (2). Stained slides were scored in terms of intensity and distribution. Normal endometrial samples uniformly showed diffuse and strong IFITM1 staining. Endometrial stromal neoplasms, particularly low-grade endometrial stromal sarcoma, showed higher IFITM1 expression compared with smooth muscle neoplasms (P<0.0001). IFITM1 immunohistochemistry has high sensitivity and specificity, particularly in the distinction between low-grade endometrial stromal sarcoma and leiomyoma (81.2 and 86.7%, respectively). Our results indicate that IFITM1 is a sensitive and specific marker of endometrial stromal differentiation across the spectrum from proliferative endometrium to metastatic stromal sarcoma. IFITM1 is a potential valuable addition to immunohistochemical panels used in the diagnosis of cellular mesenchymal uterine tumors. Further studies with larger number of cases are necessary to corroborate this impression and determine the utility of IFITM1 in routine practice. This study is a clear example of how bioinformatics, particularly tools for mining genomic and proteomic databases, can enhance and accelerate biomarker development in diagnostic pathology.</description><identifier>ISSN: 0893-3952</identifier><identifier>EISSN: 1530-0285</identifier><identifier>DOI: 10.1038/modpathol.2013.123</identifier><identifier>PMID: 24072182</identifier><identifier>CODEN: MODPEO</identifier><language>eng</language><publisher>New York: Elsevier Inc</publisher><subject>631/114 ; 631/136/142 ; 692/308/1892 ; 692/699/67/1517/1931 ; Antigens, Differentiation - analysis ; Bioinformatics ; Biomarkers ; Biomarkers, Tumor - analysis ; Cell Differentiation ; Computational Biology ; Databases, Protein ; Endometrial Neoplasms - chemistry ; Endometrial Neoplasms - pathology ; endometrial stroma ; endometrial stromal neoplasms ; Endometrial Stromal Tumors - chemistry ; Endometrial Stromal Tumors - pathology ; Endometrium ; Female ; Fibroids ; Humans ; IFITM1 ; Immunohistochemistry ; Interferon ; Laboratory Medicine ; Medicine ; Medicine & Public Health ; original-article ; Pathology ; Predictive Value of Tests ; Prognosis ; Protein expression ; Proteins ; Sarcoma ; Smooth muscle ; Stromal Cells - chemistry ; Stromal Cells - pathology ; Tumors</subject><ispartof>Modern pathology, 2014-04, Vol.27 (4), p.569-579</ispartof><rights>2014 United States & Canadian Academy of Pathology</rights><rights>United States & Canadian Academy of Pathology 2014</rights><rights>Copyright Nature Publishing Group Apr 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c538t-e24f28629a41aefe0ddc0a5f3767780541e183beec5cd7422c9670147defda4d3</citedby><cites>FETCH-LOGICAL-c538t-e24f28629a41aefe0ddc0a5f3767780541e183beec5cd7422c9670147defda4d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/1511838248?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,64385,64387,64389,72469</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24072182$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Parra-Herran, Carlos E</creatorcontrib><creatorcontrib>Yuan, Liping</creatorcontrib><creatorcontrib>Nucci, Marisa R</creatorcontrib><creatorcontrib>Quade, Bradley J</creatorcontrib><title>Targeted development of specific biomarkers of endometrial stromal cell differentiation using bioinformatics: the IFITM1 model</title><title>Modern pathology</title><addtitle>Mod Pathol</addtitle><addtitle>Mod Pathol</addtitle><description>When classifying cellular uterine mesenchymal neoplasms, histological distinction of endometrial stromal from smooth muscle neoplasms can be difficult. The only widely established marker of endometrial stromal differentiation, CD10, has marginal specificity. We took a bioinformatics approach to identify more specific markers of endometrial stromal differentiation by searching the Human Protein Atlas, a public database of protein expression profiles. After screening the database using different methods, interferon-induced transmembrane protein 1 (IFITM1) was selected for further analysis. Immunohistochemistry for IFITM1 was performed using tissue sections from the selected cases of proliferative endometrium (22), secretory endometrium (6), inactive endometrium (19), adenomyosis (10), conventional leiomyoma (11), cellular leiomyoma (16), endometrial stromal nodule (2), low-grade endometrial stromal sarcoma (16), high-grade endometrial stromal sarcoma (2) and undifferentiated uterine sarcoma (2). Stained slides were scored in terms of intensity and distribution. Normal endometrial samples uniformly showed diffuse and strong IFITM1 staining. Endometrial stromal neoplasms, particularly low-grade endometrial stromal sarcoma, showed higher IFITM1 expression compared with smooth muscle neoplasms (P<0.0001). IFITM1 immunohistochemistry has high sensitivity and specificity, particularly in the distinction between low-grade endometrial stromal sarcoma and leiomyoma (81.2 and 86.7%, respectively). Our results indicate that IFITM1 is a sensitive and specific marker of endometrial stromal differentiation across the spectrum from proliferative endometrium to metastatic stromal sarcoma. IFITM1 is a potential valuable addition to immunohistochemical panels used in the diagnosis of cellular mesenchymal uterine tumors. Further studies with larger number of cases are necessary to corroborate this impression and determine the utility of IFITM1 in routine practice. This study is a clear example of how bioinformatics, particularly tools for mining genomic and proteomic databases, can enhance and accelerate biomarker development in diagnostic pathology.</description><subject>631/114</subject><subject>631/136/142</subject><subject>692/308/1892</subject><subject>692/699/67/1517/1931</subject><subject>Antigens, Differentiation - analysis</subject><subject>Bioinformatics</subject><subject>Biomarkers</subject><subject>Biomarkers, Tumor - analysis</subject><subject>Cell Differentiation</subject><subject>Computational Biology</subject><subject>Databases, Protein</subject><subject>Endometrial Neoplasms - chemistry</subject><subject>Endometrial Neoplasms - pathology</subject><subject>endometrial stroma</subject><subject>endometrial stromal neoplasms</subject><subject>Endometrial Stromal Tumors - chemistry</subject><subject>Endometrial Stromal Tumors - pathology</subject><subject>Endometrium</subject><subject>Female</subject><subject>Fibroids</subject><subject>Humans</subject><subject>IFITM1</subject><subject>Immunohistochemistry</subject><subject>Interferon</subject><subject>Laboratory Medicine</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>original-article</subject><subject>Pathology</subject><subject>Predictive Value of Tests</subject><subject>Prognosis</subject><subject>Protein expression</subject><subject>Proteins</subject><subject>Sarcoma</subject><subject>Smooth muscle</subject><subject>Stromal Cells - chemistry</subject><subject>Stromal Cells - pathology</subject><subject>Tumors</subject><issn>0893-3952</issn><issn>1530-0285</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kT9vFDEQxS0EIkfgC1AgSzQ0e_jvrQ_RRBGBk4Jojtry2eOLw6692N5INHx2vLoQIYpUlmZ-b-Z5HkKvKVlTwtX7MbnJ1Js0rBmhfE0Zf4JWVHLSEabkU7Qiass7vpXsDL0o5ZYQKqRiz9EZE6RnVLEV-r03-QgVHHZwB0OaRogVJ4_LBDb4YPEhpNHkH5DLUobo0gg1BzPgUnNrDdjCMGAXvIfcxMHUkCKeS4jHRRyiT3lsRVs-4HoDeHe123-luLmH4SV65s1Q4NX9e46-X33aX37prr993l1eXHdWclU7YMIztWFbI6gBD8Q5S4z0vN_0vSJSUKCKHwCstK4XjNntpm-_7R14Z4Tj5-jdae6U088ZStVjKItvEyHNRVNJmZSiV5uGvv0PvU1zjs3dQrU1ignVKHaibE6lZPB6yqHd6ZemRC_p6Id09JKObuk00Zv70fNhBPcg-RtHA_gJKK0Vj5D_2f3Y2I8nFbQL3oWmKjZAtOBCBlu1S-Ex-R_UiLXG</recordid><startdate>20140401</startdate><enddate>20140401</enddate><creator>Parra-Herran, Carlos E</creator><creator>Yuan, Liping</creator><creator>Nucci, Marisa R</creator><creator>Quade, Bradley J</creator><general>Elsevier Inc</general><general>Nature Publishing Group US</general><general>Elsevier Limited</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20140401</creationdate><title>Targeted development of specific biomarkers of endometrial stromal cell differentiation using bioinformatics: the IFITM1 model</title><author>Parra-Herran, Carlos E ; Yuan, Liping ; Nucci, Marisa R ; Quade, Bradley J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c538t-e24f28629a41aefe0ddc0a5f3767780541e183beec5cd7422c9670147defda4d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>631/114</topic><topic>631/136/142</topic><topic>692/308/1892</topic><topic>692/699/67/1517/1931</topic><topic>Antigens, Differentiation - analysis</topic><topic>Bioinformatics</topic><topic>Biomarkers</topic><topic>Biomarkers, Tumor - analysis</topic><topic>Cell Differentiation</topic><topic>Computational Biology</topic><topic>Databases, Protein</topic><topic>Endometrial Neoplasms - chemistry</topic><topic>Endometrial Neoplasms - pathology</topic><topic>endometrial stroma</topic><topic>endometrial stromal neoplasms</topic><topic>Endometrial Stromal Tumors - chemistry</topic><topic>Endometrial Stromal Tumors - pathology</topic><topic>Endometrium</topic><topic>Female</topic><topic>Fibroids</topic><topic>Humans</topic><topic>IFITM1</topic><topic>Immunohistochemistry</topic><topic>Interferon</topic><topic>Laboratory Medicine</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>original-article</topic><topic>Pathology</topic><topic>Predictive Value of Tests</topic><topic>Prognosis</topic><topic>Protein expression</topic><topic>Proteins</topic><topic>Sarcoma</topic><topic>Smooth muscle</topic><topic>Stromal Cells - chemistry</topic><topic>Stromal Cells - pathology</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Parra-Herran, Carlos E</creatorcontrib><creatorcontrib>Yuan, Liping</creatorcontrib><creatorcontrib>Nucci, Marisa R</creatorcontrib><creatorcontrib>Quade, Bradley J</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>Proquest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Modern pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Parra-Herran, Carlos E</au><au>Yuan, Liping</au><au>Nucci, Marisa R</au><au>Quade, Bradley J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Targeted development of specific biomarkers of endometrial stromal cell differentiation using bioinformatics: the IFITM1 model</atitle><jtitle>Modern pathology</jtitle><stitle>Mod Pathol</stitle><addtitle>Mod Pathol</addtitle><date>2014-04-01</date><risdate>2014</risdate><volume>27</volume><issue>4</issue><spage>569</spage><epage>579</epage><pages>569-579</pages><issn>0893-3952</issn><eissn>1530-0285</eissn><coden>MODPEO</coden><abstract>When classifying cellular uterine mesenchymal neoplasms, histological distinction of endometrial stromal from smooth muscle neoplasms can be difficult. The only widely established marker of endometrial stromal differentiation, CD10, has marginal specificity. We took a bioinformatics approach to identify more specific markers of endometrial stromal differentiation by searching the Human Protein Atlas, a public database of protein expression profiles. After screening the database using different methods, interferon-induced transmembrane protein 1 (IFITM1) was selected for further analysis. Immunohistochemistry for IFITM1 was performed using tissue sections from the selected cases of proliferative endometrium (22), secretory endometrium (6), inactive endometrium (19), adenomyosis (10), conventional leiomyoma (11), cellular leiomyoma (16), endometrial stromal nodule (2), low-grade endometrial stromal sarcoma (16), high-grade endometrial stromal sarcoma (2) and undifferentiated uterine sarcoma (2). Stained slides were scored in terms of intensity and distribution. Normal endometrial samples uniformly showed diffuse and strong IFITM1 staining. Endometrial stromal neoplasms, particularly low-grade endometrial stromal sarcoma, showed higher IFITM1 expression compared with smooth muscle neoplasms (P<0.0001). IFITM1 immunohistochemistry has high sensitivity and specificity, particularly in the distinction between low-grade endometrial stromal sarcoma and leiomyoma (81.2 and 86.7%, respectively). Our results indicate that IFITM1 is a sensitive and specific marker of endometrial stromal differentiation across the spectrum from proliferative endometrium to metastatic stromal sarcoma. IFITM1 is a potential valuable addition to immunohistochemical panels used in the diagnosis of cellular mesenchymal uterine tumors. Further studies with larger number of cases are necessary to corroborate this impression and determine the utility of IFITM1 in routine practice. This study is a clear example of how bioinformatics, particularly tools for mining genomic and proteomic databases, can enhance and accelerate biomarker development in diagnostic pathology.</abstract><cop>New York</cop><pub>Elsevier Inc</pub><pmid>24072182</pmid><doi>10.1038/modpathol.2013.123</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0893-3952 |
| ispartof | Modern pathology, 2014-04, Vol.27 (4), p.569-579 |
| issn | 0893-3952 1530-0285 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1512554786 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; ProQuest Central UK/Ireland; Alma/SFX Local Collection |
| subjects | 631/114 631/136/142 692/308/1892 692/699/67/1517/1931 Antigens, Differentiation - analysis Bioinformatics Biomarkers Biomarkers, Tumor - analysis Cell Differentiation Computational Biology Databases, Protein Endometrial Neoplasms - chemistry Endometrial Neoplasms - pathology endometrial stroma endometrial stromal neoplasms Endometrial Stromal Tumors - chemistry Endometrial Stromal Tumors - pathology Endometrium Female Fibroids Humans IFITM1 Immunohistochemistry Interferon Laboratory Medicine Medicine Medicine & Public Health original-article Pathology Predictive Value of Tests Prognosis Protein expression Proteins Sarcoma Smooth muscle Stromal Cells - chemistry Stromal Cells - pathology Tumors |
| title | Targeted development of specific biomarkers of endometrial stromal cell differentiation using bioinformatics: the IFITM1 model |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T17%3A09%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Targeted%20development%20of%20specific%20biomarkers%20of%20endometrial%20stromal%20cell%20differentiation%20using%20bioinformatics:%20the%20IFITM1%20model&rft.jtitle=Modern%20pathology&rft.au=Parra-Herran,%20Carlos%20E&rft.date=2014-04-01&rft.volume=27&rft.issue=4&rft.spage=569&rft.epage=579&rft.pages=569-579&rft.issn=0893-3952&rft.eissn=1530-0285&rft.coden=MODPEO&rft_id=info:doi/10.1038/modpathol.2013.123&rft_dat=%3Cproquest_cross%3E1512554786%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1511838248&rft_id=info:pmid/24072182&rft_els_id=S089339522201849X&rfr_iscdi=true |